The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FDA grants CLR 131 fast track designation for the treatment of patients with lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia
On May 26, 2020, CLR 131, a radiotherapeutic phospholipid drug conjugate, was granted fast track designation by the U.S. Food and Drug Administration for the treatment of patients with lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia (LPL/WM) who received ≥ 2 prior treatment regimens.1
The fast track designation was based on the ongoing phase II CLOVER-1 trial (NCT02952508) which is evaluating CLR 131 in patients with relapsed/refractory B-cell malignancies, including LPL/WM and multiple myeloma.1 The dose-exploration portion of the study, Part A, demonstrated 100% overall response rates in patients with LPL/WM at 50 mCi (n = 2) and 75 mCi (n = 2) total body doses.2 The expansion cohort portion of the study, Part B, evaluating 100 mCi total body dose of CLR 131, showed that all patients (n = 4) with LPL/WM achieved 100% of overall response rate. One patient achieved a complete response rate,1 which is continuing for approximately 27 months.2
CLR 131 was previously granted Orphan Drug designation in LPL, and a fast track designation for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content